 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || zelminemab (AMG 301) / Amgen, Novartis, Lu AG09222 / Lundbeck
Review, Journal: From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment. (Pubmed Central) - Nov 28, 2023
In light of recent advances in PACAP research, we emphasize the potential of PACAP as a promising target for migraine treatment, highlighting the significance of exploring PACAP as a member of the antimigraine armamentarium, especially for patients who do not respond to or contraindicated to anti-CGRP therapies. By updating our knowledge of PACAP and its unique contribution to migraine pathophysiology, we can pave the way for reinforcing PACAP and other secretin peptides, including VIP, as a novel treatment option for migraines.
- || zelminemab (AMG 301) / Amgen, Novartis, Lu AG09222 / Lundbeck
Review, Journal: Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. (Pubmed Central) - Mar 5, 2021
Theoretically, if these antibodies block the activation of the trigeminovascular system, they will prevent the onset of migraine attacks. There are still knowledge gaps in the role of PACAP in migraine and the risk/benefit ratio of anti-PACAP antibodies must be carefully studied.
- |||| zelminemab (AMG 301) / Amgen, Novartis
Trial completion: Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention (clinicaltrials.gov) - Feb 6, 2019
P2a, N=343, Completed, Sponsor: Amgen
There are still knowledge gaps in the role of PACAP in migraine and the risk/benefit ratio of anti-PACAP antibodies must be carefully studied. Active, not recruiting --> Completed
- ||| zelminemab (AMG 301) / Amgen, Novartis
Enrollment closed: Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention (clinicaltrials.gov) - Aug 10, 2018
P2a, N=343, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| zelminemab (AMG 301) / Amgen, Novartis
Enrollment open: Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention (clinicaltrials.gov) - Sep 15, 2017
P2a, N=335, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| zelminemab (AMG 301) / Amgen, Novartis
New P2a trial: Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention (clinicaltrials.gov) - Aug 2, 2017
P2a, N=335, Not yet recruiting, Sponsor: Amgen